QIAGEN N.V. (QGEN) Stock News

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

QIAGEN N.V.: QIAGEN Announces Strong Preliminary Q1 2025 Results and Updates Full-Year 2025 Adjusted Earnings per Share Outlook

Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance

Qiagen (QGEN) shares up premarket after disclosing strong preliminary Q1 2025 results and raising full-year EPS outlook. Stock price up 3.06%.

Mentions: EKG GNOM

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

Investment adviser: 3 signs you're receiving trustworthy trading advice

Red Panda Stock Club founder Ian Dunlap has some suggestions for those trying to decipher exactly who to trust in a landscape where many claim to be experts.

Mentions: AAPL JPM SPAX NVDA ...

Qiagen Earnings Review: Q4 Summary

Apetito readies plans for new frozen meals facility in UK

The UK unit of the Germany-based business is building the new site next to existing premises in Trowbridge, Wiltshire.

Mentions: TECH GRAL BLK TSLA

Bio-Techne Opens New Customer Experience Centre in Germany

TECH announces the opening of a new Customer Experience Centre to support long-term growth in the EMEA region. The new facility is located in Dusseldorf, Germany.

Mentions: TMO BIO TECH

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

2 Recent Stock Splits You've Never Heard of That Certain Wall Street Analysts Think Could Soar 39% and 62%

Mentions: MTH

QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region

QIAGEN delivers solid Q4 2024 growth ahead of outlook

QIAGEN receives positive court decision reaffirming an important QuantiFERON-TB patent

QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $300 Million

QIAGEN N.V. to Release Results for Q4 2024 and Hold Webcast

QIAGEN to Return Approximately $300 Million to Shareholders Through a Synthetic Share Repurchase

QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples

QIAGEN secures U.S. clearance for first QIAstat-Dx mini gastrointestinal panel to support year-round outpatient care

QIAGEN Supports UK Initiative to Sequence Genomes of 100,000 Newborns With Expert-Curated Genomic Content

QIAGEN Launches AI-Extension of Ingenuity Pathway Analysis for Automatic Interpretation of Biological Data

QIAGEN Reaches Milestone With Over 1,000 Placements of EZ2 Connect Sample Preparation Instrument, Driving Laboratory Automation

QIAGEN Strengthens QIAstat-Dx With New Barcelona Site to Drive Growth in Infectious Diseases and Precision Medicine Testing

QIAGEN führt neuartige Tools zur Anpassung von digitalen PCR‑Assays und NGS-Panels für die mikrobielle Analyse ein

QIAGEN führt das erste Design-Tool für individuell anpassbare digitale PCR-Assays im Markt ein, ausgestattet mit fortschrittlichen Design-Algorithmen für...

QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis

QIAGEN introduces market’s first customizable digital PCR assay design tool with advanced design algorithms tailored for diverse microbial applications and...

QIAGEN übertrifft Prognose für drittes Quartal 2024 mit solidem Wachstum und erhöht Jahresprognose für bereinigten Gewinn je Aktie

Q3 2024: Konzernumsatz von $502 Mio. (+5% bei tatsächlichen Kursen, +6% bei konstanten Wechselkursen, CER); verwässerter Gewinn je Aktie von $0,44 und...